Governor helps cut ribbon on Mayne Pharma’s new $80M commercial manufacturing facility
Mayne Pharma’s new $80M manufacturing facility positions Metrics Contract Services to offer ‘concept to commercialization’
Mayne Pharma officials were joined by the Governor of North Carolina, Roy Cooper, on April 17 to cut a ceremonial ribbon signifying the official opening of the company’s new $80-million, oral solid-dose commercial manufacturing facility in Greenville, N.C.
The new facility enables Metrics Contract Services — Mayne Pharma’s contract development division — to offer clients a comprehensive “concept to commercialization” solution under one FDA site registration.
With the ability to offer clients downstream commercial manufacturing services, Metrics can deliver larger scale and increased capabilities for seamless scale-up, and reduce or eliminate the need for site transfers.
Specifically designed for containment, the new facility can readily manage the commercial-scale manufacturing of potent compounds — a key growth area for pharma companies today as they develop increasingly complex drugs for the treatment of cancer and chronic diseases. Each of the 13 production suites in the new facility was engineered to meet today’s stringent manufacturing demands for mitigating cross contamination — while also offering flexible space and delivering a broad range of capabilities and services. Key features include:
- Single-pass air and multiple distinct and strategically placed airlocks for gowning, material and equipment.
- Segregated product corridors.
- 100-percent HEPA-in and HEPA-out filtered air.
- Dedicated quality control laboratories.
- Commercial scale up to 450kg per batch.
Metrics provides formulation development and analytical chemistry testing services to more than 100 third-party clients worldwide.
“In 2012, Mayne Pharma entered the United States through a merger with Greenville-based Metrics, and this merger was truly transformative for us,” said Scott Richards, CEO of Mayne Pharma Group Limited.
“Mayne Pharma gained an operating platform in the world’s largest pharmaceutical market, and the combined business became more diversified in terms of products, geographies and manufacturing technologies,” he added. “The expanded supplier and customer base has led to many successful business opportunities that have fueled our growth. Most importantly, the combined workforce has shared a common goal of developing and manufacturing medicines that are efficacious, safe and affordable.”
The facility — which took two years to build — is among $100 million worth of investments Mayne Pharma has committed to infrastructure. Other investments include the new Stability Center of Excellence, which opened last year, as well as research and development.
Another infrastructure investment underway now is the repurposing the former manufacturing facility to expand pre-commercial services offered by Metrics
— specifically, increasing by 85 percent labs and manufacturing suites dedicated to formulation development and analytical chemistry activities.
“Our capacity at Metrics for handling projects ranging from pre-clinical development to Phase III clinical trial material manufacturing will be growing significantly, thanks to our expanded lab space and formulation development and manufacturing suites,” said Kimberly McClintock, executive vice president at Metrics.
To take a virtual tour of our new commercial manufacturing facility, click here.
The commercial manufacturing facility was built to readily accommodate visitors and tours without affecting personnel or workflow, and a member of the business development team at Metrics would welcome the chance to show you in person the facility and its many features. Please contact us to schedule a tour or learn more about us.